ClinicalTrials.gg
CompletedNCT06004167Updated Oct 15, 2026Results posted

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

An interventional study of Adaptive Bridging Radiation Therapy (ABRT) in Lymphoma, B-Cell, Relapsed Cancer and Refractory Lymphoma, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Enrollment
800th of 963
10 · median 37
Started
2024
with 27 others
No phase
57 of 1,131
3 open now
Registered
1,039th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 800th largest by enrollment of the 963 interventional ones that give a count, is one of 28 that started in 2024, is one of 57 with no phase, and was the 1,039th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.

This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy.

In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.

Read the detailed description

This is a feasibility/pilot study of 5 Gy adaptive radiation administered every 5 business days (1 week apart) for 5 weeks prior to standard of care CAR T-cell therapy infusion. Approximately 10 participants with Relapsed/Refractory B-cell Lymphoma will take part in this research study. The primary objective is to assess the feasibility of once weekly radiation therapy for 5 weeks.

03

Conditions studied

  • Lymphoma, B-Cell
  • Relapsed Cancer
  • Refractory Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Mediastinal Large B-cell Lymphoma
  • High-grade B-cell Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma

Keywords

  • Relapsed/Refractory B-cell Lymphoma
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 10 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of B-cell lymphoma (including, but not limited to diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from follicular lymphoma, follicular, and mantle cell lymphoma)
  • Being planned to undergo CAR T-cell therapy (patients can be enrolled prior to apheresis)
  • At least 1 according to the Lugano criteria35. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. Re-irradiation is allowed for these patients. More than 1 lesion can be targeted as per radiation oncologist discretion. If disease is palpable, physical examination alone may be sufficient measurement for disease if a recent PET/CT or CT is not available as a radiologic measurement of the disease can be obtained during CT simulation.
  • Age ≥ 18 years
  • (ECOG) performance status of less than or equal to 3.
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Any medical condition likely to interfere with assessment of safety or efficacy of RT.
  • CNS-only disease as the site for bridging radiation therapy (which cannot be reliably evaluated on CT). Patients with CNS disease with extra-axial involvement that can be evaluated on CT remain eligible.
  • Patient likely unable to lay supine for 45 minutes
  • Women of who are pregnant because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been for at least 2 years are not considered to be of childbearing potential
  • In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    5-5-5 Adaptive Bridging Radiation Therapy (ABRT)

    5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion

    Radiation: Adaptive Bridging Radiation Therapy (ABRT)

Interventions

  • RadiationAdaptive Bridging Radiation Therapy (ABRT)

    Radiation Therapy

07

What researchers measure

Primary outcomes

  1. Feasibility: Percent of Patients Able to Undergo Once-weekly ABRT

    Feasibility is being measured based on the percentage of patients being able to undergo ABRT

    Time frame: From initial CBCT acquisition to the end of ABRT treatment (5-9 weeks total).

Secondary outcomes

  1. Adverse Events

    Adverse events will be classified and graded according to the CTCAE v.5.0.

    Time frame: Adverse events were recorded at enrollment, during treatment at each fraction, and 30 and 90 days post CAR T-cell treatment, up to 25 weeks in total.

  2. In-field Disease Response at 30 and 90 Days Post CAR T-cell Therapy

    The time frame of the reported in-field disease response data is the duration of response (DOR). The median DOR for patients with a complete response (CR) was 4.9 months (2.9-6.5 months) and 2.4 months (0.5-7.4 months) for patients with disease progression (DP). Partial response and stable disease were not observed. In-field disease response is assessed using PET/CT with Deauville scoring: CR: compatible with Deauville score of 1-3 on PET/CT PR: compatible with Deauville score of 4-5 on PET/CT, with shrinkage as compared to CT simulation scan SD: compatible with Deauville score of 4-5 on PET/CT, with size stable compared to CT simulation scan DP: compatible with Deauville score of 4-5 on PET/CT, with increase in size compared to CT simulation scan

    Time frame: Patients were assessed at 30 and day 90 following CAR T-cell infusion (approximately 11 weeks and 19 weeks post enrollment, respectively). See outcome measure description for details on the time frames of the reported data.

08

Results

Posted Oct 15, 2026

Participant flow

Patients were recruited between January 2024 and May 2024 at Massachusetts General Hospital.

Participant flow — Overall Study
Milestone5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Started10
Completed10
Not completed0

Outcome measures

PrimaryFeasibility: Percent of Patients Able to Undergo Once-weekly ABRT

Feasibility is being measured based on the percentage of patients being able to undergo ABRT

Time frame:
From initial CBCT acquisition to the end of ABRT treatment (5-9 weeks total).
Reported as:
Count of participants · Participants
Feasibility: Percent of Patients Able to Undergo Once-weekly ABRT
Participants5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Patients who achieved complete response10
SecondaryAdverse Events

Adverse events will be classified and graded according to the CTCAE v.5.0.

Time frame:
Adverse events were recorded at enrollment, during treatment at each fraction, and 30 and 90 days post CAR T-cell treatment, up to 25 weeks in total.
Reported as:
Count of participants · Participants
Adverse Events
Participants5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Cytokine Release Syndrome (gr. 3 or higher)0
Immune Effector Cell-Associated Neurotoxicity Syndrome (gr. 3 or higher)3
SecondaryIn-field Disease Response at 30 and 90 Days Post CAR T-cell Therapy

The time frame of the reported in-field disease response data is the duration of response (DOR). The median DOR for patients with a complete response (CR) was 4.9 months (2.9-6.5 months) and 2.4 months (0.5-7.4 months) for patients with disease progression (DP). Partial response and stable disease were not observed. In-field disease response is assessed using PET/CT with Deauville scoring: CR: compatible with Deauville score of 1-3 on PET/CT PR: compatible with Deauville score of 4-5 on PET/CT, with shrinkage as compared to CT simulation scan SD: compatible with Deauville score of 4-5 on PET/CT, with size stable compared to CT simulation scan DP: compatible with Deauville score of 4-5 on PET/CT, with increase in size compared to CT simulation scan

Time frame:
Patients were assessed at 30 and day 90 following CAR T-cell infusion (approximately 11 weeks and 19 weeks post enrollment, respectively). See outcome measure description for details on the time frames of the reported data.
Reported as:
Count of participants · Participants
In-field Disease Response at 30 and 90 Days Post CAR T-cell Therapy
Participants5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Complete Response (CR)7
Partial Response (PR)0
Stable Disease (SD)0
Disease Progression (DP)3

Adverse events

Collected over From start of ABRT to 90 days post-CAR T Therapy (up to 25 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5-5-5 Adaptive Bridging Radiation Therapy (ABRT)1/10 (10%)0/10 (0%)8/10 (80%)
Most frequent other events
Showing 10 of 17
Most frequent other events
Event5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
White blood cell count decreasedBlood and lymphatic system disorders4/10
Lymphocyte Count DecreasedBlood and lymphatic system disorders4/10
Neutrophil cout decreasedBlood and lymphatic system disorders4/10
In-field recurrenceNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/10
Immune effector cell-associated neurotoxicity syndromeImmune system disorders3/10
AnemiaBlood and lymphatic system disorders3/10
Pelvic painReproductive system and breast disorders2/10
LymphedemaVascular disorders1/10
ParesthesiaNervous system disorders1/10
Spinal cord compressionNervous system disorders1/10

Baseline characteristics

No difference between Baseline participant count and Participant flow count.

Age, Continuous
Age, Continuous(years)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Median70 (59 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Female7
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Race/Ethnicity — White, Non-Hispanic8
Race/Ethnicity — Other, more than one race2
Histopathology
Histopathology(Participants)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
DLBCL (diffuse large B-cell lymphoma)5
TFL (transformed follicular lymphoma)3
HGBCL (high-grade B-cell lymphoma) with MYC and BCL2 oncogene rearrangements1
Waldenstrom's macroglobulinemia1
Cell of Origin
Cell of Origin(Participants)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
GCB (Germinal center B-cell)4
Non-GCB (Non-Germinal center B-cell)6
Stage at time of diagnosis
Stage at time of diagnosis(Participants)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
I3
II2
IV5
Age at the time of diagnosis
Age at the time of diagnosis(Years)5-5-5 Adaptive Bridging Radiation Therapy (ABRT)
Median67 (55 to 74)
09

Study locations

2 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
10

References and documents

Publications

  • Ababneh HS, Ng AK, Wan J, Walburn T, Zhu L, Bobic M, Johnson PC, Bredtfeld J, Leeman J, Soumerai J, Abramson JS, Barnes J, Takvorian R, Frigault MJ, Pursley J, Patel CG. 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2025 Jul 15;122(4):936-948. doi: 10.1016/j.ijrobp.2025.03.023. Epub 2025 Apr 3. PubMed 40178467 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2024, 8 months.

Results were first posted in Oct 2026, 2 years after primary completion.

Of 40 non-industry interventional studies with no phase under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 144. This study's 8 months is below that.

Counting every sponsor, half of 41 studies reached it within 73 months; a quarter within 42 and three quarters within 137.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 22, 2023
StartActual
Jan 14, 2024
Primary completionActual
Oct 1, 2024
CompletionActual
Dec 1, 2024
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFeasibility: Percent of patients ablePatients Able to undergoUndergo Once-weekly ABRTTime frame: 20 months → From initial CBCT acquisition to the end of ABRT treatment (5-9 weeks total).
Oct 15, 2026
Secondary outcomes
1 edited, 1 time frame changed
What changed in the outcomes
  • ChangedBefore Objective Response Rate (ORR)Now In-field Disease Response at 30 and 90 Days Post CAR T-cell TherapyTime frame: 15 months → Patients were assessed at 30 and day 90 following CAR T-cell infusion (approximately 11 weeks and 19 weeks post enrollment, respectively). See outcome measure description for details on the time frames of the reported data.
  • Time frameAdverse Events20 months → Adverse events were recorded at enrollment, during treatment at each fraction, and 30 and 90 days post CAR T-cell treatment, up to 25 weeks in total.
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFeasibility: Percent of patients ablePatients Able to undergoUndergo Once-weekly ABRTTime frame: 20 months → From initial CBCT acquisition to the end of ABRT treatment (5-9 weeks total).
    Secondary outcomes 1 edited, 1 time frame changed
    What changed in the outcomes
    • ChangedBefore Objective Response Rate (ORR)Now In-field Disease Response at 30 and 90 Days Post CAR T-cell TherapyTime frame: 15 months → Patients were assessed at 30 and day 90 following CAR T-cell infusion (approximately 11 weeks and 19 weeks post enrollment, respectively). See outcome measure description for details on the time frames of the reported data.
    • Time frameAdverse Events20 months → Adverse events were recorded at enrollment, during treatment at each fraction, and 30 and 90 days post CAR T-cell treatment, up to 25 weeks in total.
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT06004167
Responsible party
Chirayu Patel (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 22, 2023
Start date
Jan 14, 2024
Primary completion
Oct 1, 2024
Completion
Dec 1, 2024
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Chirayu Patel, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion